Overview

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Aligos Therapeutics